about
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With ImatinibThe choice of first-line chronic myelogenous leukemia treatment.Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.Milestones and monitoring.Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.Update on emerging treatments for chronic myeloid leukemia.Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.Ponatinib for chronic myeloid leukaemia: future perspectives.Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.BCR-ABL1 mutation ≠ ponatinib resistance.A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcomeDasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinibConcomitant occurrence of BCR-ABL and JAK2V617F mutationHPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia CellsChronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
P50
Q29999611-C9E37F91-8748-4FAF-9F66-7CC6E0F22404Q35221071-C0C7E848-D87C-4191-87CE-264FE556F66BQ35265868-348F6A01-06BD-4CA6-A97A-96200FA67048Q35652844-F90F51AD-7EB3-4D6A-923F-4724D6FE9BF4Q36708942-DB0D1F88-53D5-435B-93A7-4332AAB9EAA9Q36862301-8BC83AFA-F0C5-4A9B-89B2-0E8BEB1A09CAQ37273788-30044533-1C87-4C49-A723-A64AA7BCCF65Q37793484-466555A0-1176-48FA-9CAB-0F7827435FFAQ38175466-28FECE11-80CF-461E-8B8D-1D13F87F778FQ38397515-096B01A1-AE13-4EE8-BB01-5C5DC6CDDC7FQ38821809-63405E41-A663-4E50-A467-8E76750BF399Q38862637-D1460336-ABC2-442D-BF85-A4CB36BC252AQ38880679-F7D6F9CF-2FDB-4394-916C-BE0102EEC882Q38910072-006FCBC4-4746-41C5-A366-8127F7A467CDQ39799065-C905673F-7BB8-4FCE-B4C1-ECF373A6DA2BQ40217698-011F9088-597E-479B-BA70-6E29AE436BC2Q40346616-D53E33EE-327D-4277-AE17-F975C9D6C1EAQ41813901-6D569919-BEA8-4BF1-BD0E-72B22F99C412Q42236603-24157B12-D299-4B58-83D4-59434A705BF5Q42316987-EA42ECB3-3C23-4848-94B2-C9D6A183F2FBQ43262982-BE0E3749-2751-4634-A4C1-246A4077693BQ43475684-EB250AE4-4DF7-4D3D-984E-2D90D0EA1F26Q44167290-82E7BD35-707F-4A1F-90F2-0D3EA7141FFBQ44680313-5992A004-CCB4-49CA-9822-6AD58B6A5266Q45790127-AE38E12B-4CFF-476C-99F7-9AEB8F9A2458Q46252745-CEAE8B91-645C-42C7-BD6B-84FA32F2A8D8Q46494175-7C686463-EB0E-4C79-8F58-012A23A8F874Q47877989-AA12BE51-F422-450A-940E-DF8293E51F57Q48240372-1B1523AA-4950-429C-AC19-632963B77DCCQ54550232-A4EC87CD-FFCF-4E0A-BB41-010B5F86DC13Q55177555-3D9B52EB-C2D2-4732-B303-E4E2197DBF94Q56388689-059A764A-39A1-415B-8AA6-80CA3BA17B9DQ58449042-D44B2FAF-5087-4019-B8A3-48FD25C8C940Q61627778-2B70EEA2-3994-4611-8ED4-AF024FC3C7C4Q82252660-05DA19ED-82F2-4444-8063-C1C092A4833AQ91658182-F10E6C5C-EE92-4CE1-85F0-CD84911230ADQ96576908-11D59403-C116-4EF8-BDBA-CA36D792C3D7
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Carmen Fava
@ast
Carmen Fava
@en
Carmen Fava
@es
Carmen Fava
@nl
type
label
Carmen Fava
@ast
Carmen Fava
@en
Carmen Fava
@es
Carmen Fava
@nl
prefLabel
Carmen Fava
@ast
Carmen Fava
@en
Carmen Fava
@es
Carmen Fava
@nl
P106
P1153
24777922700
P21
P214
276149066621365602243
P31
P496
0000-0002-4896-981X
P734
P7859
viaf-276149066621365602243